Remdesivir (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Remdesivir" in German language version.

refsWebsite
Global rank German rank
2nd place
3rd place
low place
low place
68th place
29th place
4th place
7th place
447th place
751st place
low place
low place
low place
1,217th place
low place
low place
2,650th place
1,472nd place
low place
1,853rd place
66th place
4th place
195th place
255th place
1st place
1st place
6,515th place
412th place
low place
1,805th place
92nd place
415th place
low place
low place
low place
low place
28th place
91st place
6,690th place
low place
536th place
1,037th place
201st place
11th place
49th place
151st place
low place
low place
84th place
513th place
3,921st place
273rd place
low place
low place
3,043rd place
200th place
234th place
203rd place
458th place
30th place
766th place
46th place
low place
797th place
8,614th place
583rd place
2,374th place
1,391st place

aerzteblatt.de

akdae.de

ambeed.com

file.ambeed.com

  • Remdesivir (PDF) Sicherheitsdatenblatt. file.ambeed.com

apotheke-adhoc.de

bfarm.de

biopharmadive.com

cnn.com

edition.cnn.com

deutsche-apotheker-zeitung.de

doi.org

  • Travis K. Warren et al.: Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. In: Nature. Band 531, Nr. 7594, 2016, S. 381–385; doi:10.1038/nature17180.
  • Michael K. Lo et al.: Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. In: Science Translational Medicine. Band 11, Nr. 494, 29. Mai 2019, Artikel eaau9242; doi:10.1126/scitranslmed.aau9242.
  • M. L. Agostini, E. L. Andres, A. C. Sims u. a.: Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. In: mBio. Band 9, Nummer 2, 03 2018, S. , doi:10.1128/mBio.00221-18, PMID 29511076, PMC 5844999 (freier Volltext).
  • E. P. Tchesnokov, J. Y. Feng, D. P. Porter, M. Götte: Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. In: Viruses. Band 11, Nummer 4, April 2019, S. , doi:10.3390/v11040326, PMID 30987343, PMC 6520719 (freier Volltext).
  • M. K. Lo, R. Jordan, A. Arvey, J. Sudhamsu: GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. In: Scientific Reports. Band 7, März 2017, S. 43395, doi:10.1038/srep43395, PMID 28262699, PMC 5338263 (freier Volltext).
  • E. De Clercq: New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections. In: Chemistry, an Asian Journal. Band 14, Nummer 22, November 2019, S. 3962–3968, doi:10.1002/asia.201900841, PMID 31389664.
  • Calvin J. Gordon, Egor P. Tchesnokov, Emma Woolner, Jason K. Perry, Joy Y. Feng: Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. In: Journal of Biological Chemistry. Band 295, Nr. 20, Mai 2020, S. 6785–6797, doi:10.1074/jbc.RA120.013679, PMID 32284326, PMC 7242698 (freier Volltext).
  • Egor P. Tchesnokov, Joy Y. Feng, Danielle P. Porter, Matthias Götte: Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. In: Viruses. Band 11, Nr. 4, April 2019, S. 326, doi:10.3390/v11040326, PMID 30987343, PMC 6520719 (freier Volltext).
  • Lu Zhang, Dong Zhang, Xiaowei Wang, Congmin Yuan, Yongfang Li: 1′-Ribose cyano substitution allows Remdesivir to effectively inhibit nucleotide addition and proofreading during SARS-CoV-2 viral RNA replication. In: Physical Chemistry Chemical Physics. Band 23, Nr. 10, 18. März 2021, S. 5852–5863, doi:10.1039/D0CP05948J.
  • D. Siegel et al.: Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. In: Journal of Medicinal Chemistry. Band 60, 2017, S. 1648–1661, doi:10.1021/acs.jmedchem.6b01594.
  • Mo Wang, Lu Zhang, Xiaohong Huo, Zhenfeng Zhang, Qianjia Yuan: Catalytic Asymmetric Synthesis of the anti-COVID-19 Drug Remdesivir. In: Angewandte Chemie. Band 132, Nr. 47, 2020, S. 21000–21005, doi:10.1002/ange.202011527.
  • Veeranjaneyulu Gannedi, Bharath Kumar Villuri et al.: Practical Remdesivir Synthesis through One-Pot Organocatalyzed Asymmetric (S)-P-Phosphoramidation. In: The Journal of Organic Chemistry. Band 86, Nr. 7, 2. April 2021, S. 4977–4985, doi:10.1021/acs.joc.0c02888.
  • J. C. Alvarez, P. Moine, I. Etting, D. Annane, I. A. Larabi: Quantification of plasma remdesivir and its metabolite GS-441524 using liquid chromatography coupled to tandem mass spectrometry. Application to a Covid-19 treated patient. In: Clinical Chemistry and Laboratory Medicine. Band 58, Nr. 9, Juni 2020, S. 1461–1468, doi:10.1515/cclm-2020-0612, PMID 32573468.
  • Michael Jacobs et al.:Late Ebola virus relapse causing meningoencephalitis: a case reportIn: The Lancet. (London, England) Band 388, Nr. 10043, 2016, S. 498–503, doi:10.1016/S0140-6736(16)30386-5.
  • Sabue Mulangu: A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. In: New England Journal of Medicine. (NEJM) Band 381, 12. Dezember 2019, S. 2293–2303, doi:10.1056/NEJMoa1910993.
  • John H. Beigel, Kay M. Tomashek et al.: Remdesivir for the Treatment of Covid-19 — Final Report. In: New England Journal of Medicine. 8. Oktober 2020, doi:10.1056/NEJMoa2007764.
  • K. Ansems, F. Grundeis F, K. Dahms et al.: Remdesivir for the treatment of COVID-19. In: Cochrane Database of Systematic Reviews. Nr. 8, 2021, Artikel Nr.: CD014962, doi:10.1002/14651858.CD014962.
  • J. Grein et al.: Compassionate Use of Remdesivir for Patients with Severe Covid-19. In: The New England Journal of Medicine. 10. April 2020, doi:10.1056/NEJMoa2007016.
  • Andre C. Kalil, Thomas F. Patterson, Aneesh K. Mehta u. a.: Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. In: The New England Journal of Medicine. 2021, Nr. 384, S. 795–807, doi:10.1056/NEJMoa2031994 (Volltext Auf: nejm.org).

elpais.com

emcrit.org

europa.eu

ema.europa.eu

echa.europa.eu

ec.europa.eu

fda.gov

fda.gov

accessdata.fda.gov

general-anzeiger-bonn.de

gilead.com

heise.de

jamanetwork.com

koreatimes.co.kr

medrxiv.org

merca20.com

nature.com

nejm.org

  • Andre C. Kalil, Thomas F. Patterson, Aneesh K. Mehta u. a.: Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. In: The New England Journal of Medicine. 2021, Nr. 384, S. 795–807, doi:10.1056/NEJMoa2031994 (Volltext Auf: nejm.org).

nih.gov

ncbi.nlm.nih.gov

  • M. L. Agostini, E. L. Andres, A. C. Sims u. a.: Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. In: mBio. Band 9, Nummer 2, 03 2018, S. , doi:10.1128/mBio.00221-18, PMID 29511076, PMC 5844999 (freier Volltext).
  • E. P. Tchesnokov, J. Y. Feng, D. P. Porter, M. Götte: Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. In: Viruses. Band 11, Nummer 4, April 2019, S. , doi:10.3390/v11040326, PMID 30987343, PMC 6520719 (freier Volltext).
  • M. K. Lo, R. Jordan, A. Arvey, J. Sudhamsu: GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. In: Scientific Reports. Band 7, März 2017, S. 43395, doi:10.1038/srep43395, PMID 28262699, PMC 5338263 (freier Volltext).
  • E. De Clercq: New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections. In: Chemistry, an Asian Journal. Band 14, Nummer 22, November 2019, S. 3962–3968, doi:10.1002/asia.201900841, PMID 31389664.
  • Calvin J. Gordon, Egor P. Tchesnokov, Emma Woolner, Jason K. Perry, Joy Y. Feng: Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. In: Journal of Biological Chemistry. Band 295, Nr. 20, Mai 2020, S. 6785–6797, doi:10.1074/jbc.RA120.013679, PMID 32284326, PMC 7242698 (freier Volltext).
  • Egor P. Tchesnokov, Joy Y. Feng, Danielle P. Porter, Matthias Götte: Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. In: Viruses. Band 11, Nr. 4, April 2019, S. 326, doi:10.3390/v11040326, PMID 30987343, PMC 6520719 (freier Volltext).
  • J. C. Alvarez, P. Moine, I. Etting, D. Annane, I. A. Larabi: Quantification of plasma remdesivir and its metabolite GS-441524 using liquid chromatography coupled to tandem mass spectrometry. Application to a Covid-19 treated patient. In: Clinical Chemistry and Laboratory Medicine. Band 58, Nr. 9, Juni 2020, S. 1461–1468, doi:10.1515/cclm-2020-0612, PMID 32573468.
  • V. Avataneo, A. de Nicolò, J. Cusato u. a.: Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease. In: Journal of Antimicrobial Chemotherapy, Band 75, Nr. 7, 1. Juli 2020, S. 1772–1777, PMID 32361744.

niaid.nih.gov

npr.org

pharmazeutische-zeitung.de

pmda.go.jp

  • Special Approval for Emergency on Remdesivir for COVID-19. Pharmaceutical and Medical Devices Agency (PMDA), 8. Mai 2020; pmda.go.jp (PDF; 176 kB).

reuters.com

spiegel.de

  • Julia Koch: Irres Tempo. In: Der Spiegel. Nr. 14, 2020, S. 106 (online28. März 2020).

tagesspiegel.de

viruseradication.com

web.archive.org

  • Coronavirus SARS-CoV-2. In: bfarm.de. Bundesinstitut für Arzneimittel und Medizinprodukte, 2020, abgerufen am 10. April 2020 (die Seite wird regelmäßig aktualisiert, siehe auch Versionen vom 25. März und 10. April im Web Archive).

welt.de

who.int

wiwo.de